<DOC>
	<DOCNO>NCT01878201</DOCNO>
	<brief_summary>The purpose study Evaluate Antihypertensive efficacy Fimasartan 30 mg 24 hour Patients Mild Moderate Essential Hypertension</brief_summary>
	<brief_title>A Valsartan 80 Mg-Referenced , Therapeutic Exploratory Clinical Study Evaluate Antihypertensive Efficacy Fimasartan 30 mg During 24 Hours Patients With Mild Moderate Essential Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Antihypertensive Agents</mesh_term>
	<mesh_term>Valsartan</mesh_term>
	<criteria>1 . Subjects age 20 70 year 2 . Essential hypertension subject measure 135/85 mmHg average Diastolic Blood pressure ( DBP ) Systolic Blood pressure ( SBP ) measure ABP monitor baseline visit ( day 0 ) 3 . Subjects agree participate study submit write informed consent 4 . Subjects consider understand study , cooperative , able followedup whole study period 1 . Severe hypertension patient ; 180 mmHg mean sit SBP and/or 110 mmHg mean sit DBP measure office Blood pressure ( BP ) , Randomization ( Screening visit , Placebo runin visit , PreBaseline visit , Baseline visit ) 2 . Patients difference office BP select one arm DBP 10 mmHg and/or SBP 20 mmHg screen visit 3 . Patients secondary hypertension 4 . Patients symptomatic orthostatic hypotension 5 . Patients severe insulin dependent uncontrolled diabetes mellitus ( HbA1c &gt; 9 % , increased regimen oral hypoglycemic agent , use insulin baseline visit ) 6 . Patients severe heart disease , ischemic heart disease within 6 month , peripheral vascular disease , Percutaneous Transluminal Coronary Angiography ( PTCA ) , Coronary Artery Bypass Graft ( CABG ) 7 . Patients significant ventricular tachycardia , atrial fibrillation , atrial flutter significant arrhythmia 8 . Patients hypertrophic obstructive cardiomyopathy , severe obstructive coronary artery disease , aortic stenosis , hemodynamically significant aortic valve mitral valve disease 9 . Patients severe cerebrovascular disease within 6 month 10 . Patients know severe malignancy retinopathy within 6 month 11 . Patients waste disease , autoimmune disease , connective tissue disease 12 . Patients significant investigation abnormal renal function ( Creatinine 1.5 time upper limit normal ) , abnormal liver function ( Aspartate Transaminase ( AST ) , Alanine Transaminase ( ALT ) 2 time upper normal ) 13 . Patients surgical medical disease able affect absorption , distribution , metabolism , excretion 14 . Patients hereditary disorder galactose intolerance , Lapp lactase deficiency glucosegalactose malabsorption 15 . Patients significant investigation Hypokalemia ( Less 3.5mmol/L ) , Hyperkalemia ( exceed 5.5mmol/L ) 16 . Patients depletion body fluid sodium ion able correct 17 . Patients suspected history drug alcohol abuse within past two year 18 . Childbearing , breastfeed woman female plan become pregnancy possibility pregnancy n't prevent conception acknowledge method 19 . Patients chronic inflammation disease need chronic inflammation therapy 20 . Patients hepatitis type B type C carriers 21 . Patients laboratory test result indicate clinically significant abnormal result 22 . Patients receive medication affect blood pressure 23 . Patients history allergic reaction angiotensin II antagonist 24 . Patients medical history malignant tumor within 5years , except local basal cell carcinoma skin 25 . Patients take investigational drug within 12 week screen visit go progress clinical trial 26 . Subject judge unsuitable participate study investigator</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Fimasartan</keyword>
	<keyword>24 hour ABP monitoring ( ABPM )</keyword>
	<keyword>antihypertension</keyword>
</DOC>